bluuebunny/crossref_metadata_2025_split huggingface dataset:
143-LB: Preconception Counseling and Reproductive Education Program for Persons with Diabetes (PREPPD)
Authors: FALLURIN RESHMITHA , ROUVIERE MADELEINE , O'MALLEY GRENYE , RODRIGUEZ ORTEGA SUSEL , WANG ALLY W. , OGYAADU SELASSIE J. , LEVISTER CAMILLA , LAM DAVID W. , SHAH NIRALI , LEVY CAROL J. 
Published: June 2023

Objective: Pregnancy without preparation in people with diabetes (PWD) can lead to adverse maternal and fetal outcomes. Improved patient knowledge through effective preconception counseling can help reduce the rate of complications. We developed a quality improvement initiative to improve both patient and provider knowledge.
Methods: Interventions were implemented for PWD and providers (HCPs) at 2 underserved clinics. HCPs completed pre-intervention questionnaires (highest score of 10) about management of diabetes in pregnancy and preconception goals followed by a training lecture. PWD aged 18-50 with reproductive potential were identified to receive a survey (highest score of 6) about preconception preparation, contraceptive use, glycemic targets, and safer medications in pregnancy. HCPs used a standardized template to guide counseling during visit. PWD and HCPs completed a follow up survey 3- 6 months later.
Results: Pre-intervention surveys were completed by 75 PWD and 16 HCPs. Documentation of preconception counseling by HCPs increased from 38% to 83% post intervention. Counseling was perceived as satisfactory by 83% of PWD.
Conclusion: Process measures have improved with our pregnancy focused QI initiative. Continued enrollment and post-intervention assessment as well as expansion to include adolescent PWD will enable us to further evaluate outcome measures.

Disclosure
R. Fallurin: None. C. J. Levy: Advisory Panel; Dexcom, Inc., Research Support; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc., T1D Exchange. M. Rouviere: None. G. O'malley: Research Support; Dexcom, Inc., Abbott Diabetes, Tandem Diabetes Care, Inc., Omnipod, Eli Lilly and Company. S. Rodriguez ortega: None. A. W. Wang: None. S. J. Ogyaadu: None. C. Levister: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc., Abbott Diabetes. D. W. Lam: None. N. Shah: Research Support; Dexcom, Inc.
1434-P: Smoking, All-Cause, and Cause-Specific Mortality in Individuals with Type 2 Diabetes in Mexico—An Analysis of the Mexico City Prospective Study (MCPS)
Authors: RAMÍREZ-GARCÍA DANIEL , FERMÍN-MARTÍNEZ CARLOS A. , EDUARDO ANTONIO VILLA NEFTALI , VARGAS-VÁZQUEZ ARSENIO , FERNÁNDEZ CHIRINO LUISA , SEIGLIE JACQUELINE A. , YAXMEHEN BELLO-CHAVOLLA OMAR 
Published: June 2023

Background: Cigarette smoking increases the already elevated risk of mortality observed in adults with type 2 diabetes but prospective data on the association between smoking and mortality among Mexican adults with type 2 diabetes are lacking.
Methods: We analyzed data from the MCPS, which surveyed 150,000 adults between 1998-2004. We performed Cox proportional hazard models and Fine and Gray sub distribution hazard models to estimate adjusted relative risk for all-cause and cause-specific mortality, respectively.
Results: Among 25,141 individuals with diabetes, 50.7% were never smokers, 26% former smokers, and 23.2% active smokers. Compared to non-smokers (Fig 1A), former smokers had an increased risk of all cause-mortality at 7.5 years of follow-up (HR 1.15 [95% CI 1.05-1.26]), with this risk receding completely after 7.5 years. Compared to non-smokers (Fig 1B), active smokers had a significantly higher risk of death after 7.5 years of follow-up (HR 1.17 [95% CI 1.07-1.28]), but not in the preceding 7.5 years. For cause-specific mortality, active smokers had an increased risk of death due to myocardial infarction, lung cancer, and COPD.
Conclusions: The risk of death among Mexican adults with type 2 diabetes varies over time and according to smoking status. Strategies to support sustained smoking cessation in people with type 2 diabetes are needed.

Disclosure
D.Ramírez-garcía: None. C.A.Fermín-martínez: None. N.Antonio villa: None. A.Vargas-vázquez: None. L.Fernández chirino: None. J.A.Seiglie: Consultant; BDMT Global, Techspert Expert Network. O.Bello-chavolla: None.
1436-P: Glycemic Variability as a Risk Factor for In-Hospital Mortality among CKD, Type 2 DM Patients Admitted for COVID-19—Retrospective Cohort Study
Authors: MANGUGAN NOREEN ADA G. 
Published: June 2023

Background: COVID-19 severity is affected by multiple factors and it is theorized that better glycemic control results in lower mortality. Also, the use of glycemic variability through Time In Range (TIR) may be a better indicator of glycemic control.
Objective: To determine the association of glycemic control (ie TIR and HbA1c) during admission with in-hospital mortality among patients with COVID-19, CKD, and T2DM
Methods: A single center retrospective study was conducted on admitted CKD T2DM COVID patients from September 2020 to December 2021. Participants were excluded with mild COVID-19, post kidney transplant, no CBG monitoring, admitted for &lt; 24 hours. A survival analysis was used to determine the association of glycemic control & mortality.
Results: Among 148 patients, 42.0% (n = 63) had in-hospital mortality. Glycemic control within range was achieved in 4.7% (4 out of 85) of the survivor group and 1.6% (1 out of 63) of the non survivor group and no significant difference noted between the two groups (HR 0.41 95% CI 0.06 to 3.03). For HbA1c level on admission, no significant difference between the two groups (HR 1.22 95% CI 0.74 to 2.01).
Conclusion: This study concluded that glycemic control did not show association with in-hospital mortality among CKD T2DM patients with COVID-19 infection. Additionally, HBA1c on admission was not associated with mortality.

Disclosure
N.G.Mangugan: None.
1441-P: Index60 Stratification Enhances Current Staging for Type 1 Diabetes by Identifying At-Risk Single Islet Autoantibody Positive (Ab+) Individuals
Authors: SIMS EMILY K. , CUTHBERTSON DAVID D. , BOSI EMANUELE , EVANS-MOLINA CARMELLA , REDONDO MARIA J. , NATHAN BRANDON M. , ISMAIL HEBA M. , JACOBSEN LAURA M. , SOSENKO JAY 
Published: June 2023

The current staging system for T1D development is used for participant selection in prevention trials. This system is based on multiple Ab+ and the presence or absence of dysglycemia, but does not address C-peptide measures or single Ab+ individuals. Since a limited number of Ab+ individuals are available for trials, we used TrialNet Pathway to Prevention (TNPTP) study data to assess whether a composite glucose and C-peptide measure, Index60, could identify single Ab+ individuals (designated as Stage 0) with comparable risk to those in Stages 1 or 2 for progression to Stage 3. Table 1A compares normoglycemic Stage 0 individuals with Index60 values above the median (&gt;-0.045) of the full TNPTP cohort (n=6107) vs. those at Stage 1 with Index60 below the median (&lt; -0.045). Table 1B compares those at Stage 0 with dysglycemia and higher Index60 vs. those at Stage 2 with lower Index60. In both comparisons, Index60 stratification identified Stage 0 individuals with metabolic features characteristic of T1D (e.g., lower C-peptide with higher glucose) and comparable 5-year risk to Stage 1 or Stage 2 individuals. Thus, by considering individuals with 1 Ab and C-peptide measures, the current staging system could be improved for risk discernment and to identify appropriate eligibility for prevention trials.

Disclosure
E.K.Sims: Speaker's Bureau; Medscape, American Diabetes Association. D.D.Cuthbertson: None. E.Bosi: None. C.Evans-molina: Advisory Panel; Provention Bio, Inc., DiogenX, Avotres Inc., Neurodon, MaiCell Therapeutics, Other Relationship; Isla Technology, Bristol-Myers Squibb Company, Nimbus Therapeutics, Research Support; Lilly, Astellas Pharma Inc. M.J.Redondo: None. B.M.Nathan: None. H.M.Ismail: Consultant; Rise Therapeutics. L.M.Jacobsen: None. J.Sosenko: None.
1446-P: Success of a Hybrid Care Model to Maintain Glycemic Control in Older Adults with Type 1 Diabetes (T1D)
Authors: ADAM ATIF , MUNSHI MEDHA , HURLBERT REBECCA , SLYNE CHRISTINE , LAFFEL LORI M. , TOSCHI ELENA 
Published: June 2023

Aim: During the COVID-19 pandemic, a hybrid care (in-office and telemedicine) model was urgently implemented. Impact of this hybrid model on clinical visit frequency and glycemic outcomes in older adults with T1D warrants study.
Methods: Demographics, clinical characteristics, and clinical visits of older adults (aged ≥65 years) with T1D were retrieved from electronic medical records covering 2 time periods, before the pandemic (pre-pandemic: April 1, 2019-March 1, 2020) and during the pandemic (pandemic: September 1, 2020 to August 31, 2021) periods, with adjustment for length of follow-up.
Results: 661 (45% male) unique older adults with T1D received care and had HbA1c measurements in both periods at a tertiary diabetes center. Mean age was 72±5 years; 59% were CGM users, 38% were pump users. Clinic visits in the pre-pandemic period were almost all in-person, averaging 4.2 visits/person/year (CI 3.9-4.4), with &lt;2% as phone visits. During the pandemic period, the mean number of visits was significantly greater than in the pre-pandemic period, at 6.3 visits/person/year (CI 5.7-6.9), with 30% in-office, 38% by video, and 32% by phone. HbA1c values were similar between periods (pre-pandemic: 7.6% (CI 7.5-7.8) vs pandemic: 7.4% (CI 7.3-7.6)). However, there was a significant, favorable shift in HbA1c distribution &lt;7%, 7-8%, &gt;8% when using hybrid care model: pre-pandemic period 21, 42, 37%, respectively; pandemic period 35, 36, 29%, respectively (pre-pandemic vs pandemic period p&lt;.0.001).
Conclusion: Compared with the pre-pandemic care model, the hybrid care model during pandemic for older adults with T1D allowed for increased visit frequency and preserved HbA1c values while favorably increasing the proportion with HbA1c &lt;7% and decreasing proportion at the higher end of the distribution. This data support ongoing use of a hybrid care model for older adults with T1D.

Disclosure
A.Adam: None. M.Munshi: Consultant; Sanofi. R.Hurlbert: None. C.Slyne: None. L.M.Laffel: Advisory Panel; Medtronic, Lilly Diabetes, Novo Nordisk, Vertex Pharmaceuticals Incorporated, Roche Diagnostics, Provention Bio, Inc., Consultant; Dexcom, Inc., Janssen Pharmaceuticals, Inc., Medscape. E.Toschi: Advisory Panel; Eli Lilly and Company.

Funding
Thomas J. Beatson, Jr. Foundation
1447-P: Young Children with T1D on Three Continents—An Especially Vulnerable Group in Need of Specialized Health Care
Authors: TITTEL SASCHA R. , SANDY JESSICA L. , ROMPICHERLA SAKETH , KARGES BEATE , JAMES STEVEN , NOOR NUDRAT , ZIMMERMANN ANTHONY , MAAHS DAVID M. , HOLL REINHARD W. , CRAIG MARIA E. , EBEKOZIEN OSAGIE , FRÖHLICH-REITERER ELKE 
Published: June 2023

We aimed to identify differences in care and outcomes of very young children with T1D onset from 3 multicenter registries from three continents: T1DX-QI (US), DPV (Germany/Austria/Switzerland/Luxembourg), and ADDN (Australia/New Zealand). These results are an update of 2,011 children of this age-group treated in 2011/2012 in European/US centers (Diabetologia 57:1578-585, 2014). For treatment years 2019-2021, there were 8,004 children with T1D &lt;6 years of age in the 3 registries. The most recent treatment year per child was analyzed. To ensure data protection, analyses were pre-defined and conducted separately by each group. Age at onset, median diabetes duration and gender ratio, as well as anthropometry, and insulin requirement were very similar between the three registries (Table). In DPV, the vast majority of children in this age-group used insulin pumps and glucose sensors, followed by ADDN and T1DX-QI. HbA1c was lowest in DPV, followed by ADDN. Severe hypoglycemia and DKA were rare. Celiac disease was reported most often in Europe, while thyroid disease was more prevalent in the US. Both T1DX-QI and DPV improved metabolic control in this age-group compared to an analysis 10 years ago. However, the majority of children still do not reach currently recommended A1C levels. This young group of subjects needs extensive resources in terms of education, insulin dose adjustment, and family support.

Disclosure
S.R.Tittel: None. M.E.Craig: None. O.Ebekozien: Advisory Panel; Medtronic, Research Support; Eli Lilly and Company, Dexcom, Inc. E.Fröhlich-reiterer: None. J.L.Sandy: None. S.Rompicherla: None. B.Karges: None. S.James: None. N.Noor: None. A.Zimmermann: None. D.M.Maahs: Advisory Panel; Medtronic, LifeScan Diabetes Institute, MannKind Corporation, Consultant; Abbott, Research Support; Dexcom, Inc. R.W.Holl: None.
1448-P: Diabetes-Related Complications and Comorbid Conditions in Older Adults with Type 1 Diabetes (T1D) in a Large Geographically Diverse Health Care System
Authors: KAHKOSKA ANNA , WEINSTEIN JOSHUA M. , MUTHUKKUMAR RASHMI , YOUNG LAURA A. 
Published: June 2023

Older adults (age 65+) with T1D are an understudied population. Though many older adults may have long-standing diabetes and the prevalence of multimorbidity accumulates over the lifespan, the prevalence of diabetes-related complications and comorbid conditions in older adults with T1D have not been well-characterized, though these factors can affect quality of life. We analyzed electronic health record (EHR) data from older adults with T1D within a large public hospital system (n=560). We used ICD-10 diagnostic codes and calculated the proportion of the sample with different comorbidities and diabetes-related complications, as well as the average number of total complications and the Charlson Comorbidity Index Score (Table). The mean number of T1D-related complications was 3.93 with 29.6% (n=166) having 6+ concurrent T1D complications. The most common T1D complication was retinopathy or other ophthalmic complication with (72%; n=402). The median Charlson Comorbidity index score was 3. Nearly half of the sample (n=282; 50.4%) had cardiovascular disease and more than one third (n=197; 35%) had renal disease. These data underscore a high burden of diabetes complications and comorbidities among older adults with T1D. Understanding the medical complexity of this population can inform future research and intervention.

Disclosure
A.Kahkoska: None. J.M.Weinstein: Research Support; Dexcom, Inc. R.Muthukkumar: None. L.A.Young: Research Support; Novo Nordisk, Rhythm Pharmaceuticals, Inc., Eli Lilly and Company, Jaeb Center for Health Research, Sanofi, Boehringer-Ingelheim.

Funding
National Institutes of Health (KL2TR002490, UL1TR002489)
145-OR: Counterregulatory Response to Hypoglycemia Is Improved with Serotonin and Norepinephrine Reuptake Inhibitors
Authors: MACON ERICA L. , DEVORE MICAH H. , ILES ASHLEY , SCHOEDER LILY A. , PATEL BANSI , MUSIC MEGAN B. , FISHER SIMON 
Published: June 2023

We previously reported that serotonin and norepinephrine reuptake inhibitors, amitriptyline (AMT) and imipramine (IMP), restored hypoglycemia awareness in rodents. To test the hypothesis that AMT and IMP could prevent the development of an impaired counterregulatory response (CRR) to hypoglycemia, Sprague-Dawley rats (250-350 g) with pre-implanted arterial and jugular cannulae were randomly assigned to one of four treatment groups: 1) recurrent saline controls (RS, n=8); 2) recurrent insulin-induced hypoglycemia (RH, 30-50 mg/dl, n=8); 3) RH + AMT (10 mg/kg IP, n=8); or 4) RH + IMP (5 mg/kg IP, n=8). Following 3-days of RS/RH treatment, all groups underwent 90-minute hyperinsulinemic (50 mU.kg-1.min-1) hypoglycemic (40-45 mg/dL) clamps. Blood glucose was similar for all groups during the clamp. Glucose infusion rates during the last 30-minutes were significantly reduced for both RH+AMT (23.7 mg/kg/min) and RH+IMP (24.8 mg/kg/min) as compared to RH (40.4 mg/kg/min), indicating that both drugs improved the glucoregulatory response to hypoglycemia. In conclusion, these studies identify 1) the involvement of serotonin and norepinephrine neurotransmitter pathways in the development of blunted counterregulatory responses to hypoglycemia, 2) in subjects with blunted CRR, these drugs may be useful therapeutic agents to improve the glucoregulatory response to hypoglycemia.

Disclosure
E.L.Macon: None. M.H.Devore: None. A.Iles: None. L.A.Schoeder: None. B.Patel: None. M.B.Music: None. S.Fisher: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (DK118082)
1450-P: Profiles of Glycemic Control in People with Type 1 Diabetes Using CGM—A Clustering Approach in the SFDT1 Study
Authors: COSSON EMMANUEL , AGUAYO GLORIA A. , SABLONE LAURA , HUET MATHILDE , RIVELINE JEAN-PIERRE , FAGHERAZZI GUY ,   SFDT1STUDY TEAM
Published: June 2023

CGM-derived data are usually analyzed in silos, metric by metric, for diabetes care or therapeutic strategy. Simultaneous analysis of the various dimensions of glycemic control would allow a more comprehensive overview. We analyzed data of people with type 1 diabetes (PWT1D) in the SFDT1 cohort study. A K-means clustering model was developed with HbA1c, coefficient of variation (CV), time in range (TIR), time below 70 mg/dl (TBR), Gold score and Glycemic Risk Index (GRI). We included 618 participants (53% men, age 41±14 years) from 20 centres in France. The optimal model had 3 clusters. The “Euglycemia” cluster (n=280, 45%) was characterized by a high TIR (mean 69.3%); low TBR ​​(4.2%), TAR (time above 180 mg/dl: 26.5%), CV (35.7%), HbA1c (7.0%) and GRI (36.4) values. The “Hyperglycaemia" cluster (n=197, 32%) was characterized by high TAR (56.5%), GRI (71.8) and HbA1c (8.5%) and low TIR (40.3%), TBR (3.2%) and Gold score (2.3). The “Hypoglycemia” cluster (n=141, 23%) was characterized by high TBR (15.8%), CV (46.1%), GRI (69.2) and Gold score (3.0). Participants in the “Hyperglycemia” cluster were younger, socially vulnerable, and had more frequent hypertension than those in the “Euglycemia” cluster. To conclude, we identified three distinct, clinically relevant glycemic control profiles, enabling better characterization of PWT1D and, thus, more personalised management.

Disclosure
E.Cosson: Board Member; Abbott, Medtronic. G.A.Aguayo: None. L.Sablone: None. M.Huet: None. J.Riveline: Board Member; Abbott Diabetes, Medtronic, Dexcom, Inc., Novo Nordisk, Eli Lilly and Company, Sanofi. G.Fagherazzi: Advisory Panel; Roche Diabetes Care, Consultant; AbbVie Inc., Lilly. Sfdt1 study team: n/a.
1453-P: Remedy to Diabetes Distress (R2D2)—Identify the Relationship between HbA1c, Socioeconomic Status (SES), and Diabetes Distress (DD)
Authors: POMERANTZ RHIANNON , WILLIAMS DAVID D. , YEH HUNG-WEN , CLEMENTS MARK A. , PATTON SUSANA R. 
Published: June 2023

Objective: DD among school-age children with Type 1 Diabetes (T1D) and their parents is associated with suboptimal glycemic control. We sought to determine if SES modulates the association between parent distress and child HbA1c.
Methods: Parents completed the Problem Areas in Diabetes-Child (P-PAID-C) and reported family demographics. We measured child HbA1c using a validated fingerstick homekit. We calculated a Hollingshead Score to quantify family SES. We developed a multivariable regression model with child HbA1c as the outcome and Hollingshead Tertiles (lowest = tertile 1) and P-PAID-C scores as predictors.
Results: The sample included N = 158 parent-child dyads,[M ± SD] child age 10.20±1.49 years, HbA1c 7.96±1.63%, 50% boys, 9.3% Black, 6.2% Hispanic; 88.8% of respondents were mothers. P-PAID-C score was 59.0±18.0. Simple correlations suggested higher child HbA1c associated with higher P-PAID-C scores and lower SES. Regression results showed P-PAID-C scores as the strongest predictor of child HbA1c even when including SES and an interaction variable. (Figure.1)
Conclusion: Child HbA1c increases as a function of parent DD, but family SES does not modify this association. Parent DD may represent a treatable, underscoring a need for research testing interventions to reduce parent DD levels.

Disclosure
R.Pomerantz: None. D.D.Williams: None. H.Yeh: None. M.A.Clements: Consultant; Glooko, Inc., Research Support; Dexcom, Inc., Abbott Diabetes. S.R.Patton: None.
1457-P: Analysis of Type 1 Diabetes Trends in Israel
Authors: DUSKIN-BITAN HADAR , TIROSH AMIR , BECKENSTEIN TANYA , NETZER DORON , ARBEL RONEN , PERETZ ALON 
Published: June 2023

Background and Aim: With increased awareness of late-onset type 1 diabetes and the importance of accurate diabetes classification, there is a need to reassess the epidemiological and clinical characteristics of people with T1D (PwT1D). We report analyses of a novel population based cohort of PwT1D in Israel.
Methods: Using database of Clalit HMO in Israel, insuring 4.8M people (51.5% of the population) we established a registry of all PwT1D. Prevalence, annual incidence, assessment of anthropometric, metabolic parameters, complications, and comorbidities were analyzed.
Results: We recorded data of 13,167 PwT1D (0.27% of the population, 51.3% men), with an annual incidence of 1.05/10,000 people representing a 13% increase over the past decade. Median age at diagnosis is 22 years with 25% diagnosed at age ≥40 years. Median age of current PwT1D is 36 years with 25% are ≥55. Of note, 50% are either overweight or obese, with over 50% having metabolic abnormalities, traditionally associated with type 2 diabetes. Hypothyroidism (16.1%) and Celiac disease (4.5%) are the most prevalent autoimmune diseases in this cohort. Additional characteristics are depicted in table 1.
Conclusion: Currently, a significant proportion of PwT1D are middle aged or older, half are overweight or obese with the majority having additional characteristics of the metabolic syndrome. Efforts for accurate classification of PwT1D and addressing associated comorbidities are of key importance.

Disclosure
H.Duskin-bitan: None. A.Tirosh: Advisory Panel; Medtronic, Novo Nordisk, Sanofi, Eli Lilly and Company, Research Support; Medtronic, Sanofi, Speaker's Bureau; Medtronic, Novo Nordisk, Sanofi, Eli Lilly and Company. T.Beckenstein: None. D.Netzer: None. R.Arbel: None. A.Peretz: None.
1458-P: Challenges for the Diagnostic Classification of Type 1 Diabetes (T1D) among Older Adults in Electronic Health Record (EHR) Data
Authors: WEINSTEIN JOSHUA M. , MUTHUKKUMAR RASHMI , YOUNG LAURA A. , KAHKOSKA ANNA R. 
Published: June 2023

As T1D treatments improve and the US population ages, there is a growing number of older adults (≥65 years) with T1D. This patient population is distinct from their T2D counterparts yet remains understudied. Analyzing routine health care may yield real-world evidence to augment trial data and inform best practices. Yet, it is essential to properly classify patients with T1D vs. T2D. We aimed to assess the extent to which codes for T1D versus T2D overlap in EHR data among older adults with diabetes and assess the implications for identifying older adults with T1D, specifically. We analyzed electronic health record (EHR) data from a large, public health care system in the southeast US, including 12 affiliated hospitals and over 200 academic and community-based practices. We included data from adults ages 65+ years that had at least one code for T1D or T2D. Of the 7,436 patients withT1D or T2D listed among their medical conditions, 7,253 (97.5%) had a diagnostic code for T2D and 895 (12.0%) had a diagnostic code for T1D. Of those with a T1D code, 787 (87.9%) also had at least one T2D code. Among those with a code for T1D, the mean percentage of codes that indicate T1D is 49.4%. There is a high degree of co-occurring T1D and T2D diagnosis codes in EHR profiles of older adults, with implications for clinical care and research. Cohort classification in diabetes-oriented RWE studies warrants further research.

Disclosure
J.M.Weinstein: Research Support; Dexcom, Inc. R.Muthukkumar: None. L.A.Young: Research Support; Novo Nordisk, Rhythm Pharmaceuticals, Inc., Eli Lilly and Company, Jaeb Center for Health Research, Sanofi, Boehringer-Ingelheim. A.R.Kahkoska: None.

Funding
National Institutes of Health (KL2TR002490, UL1TR002489)